5-溴-3-甲基吡啶-2-甲腈 | 156072-86-5

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-3-甲基吡啶-2-甲腈
• 中文别名: 2-氰基-3-甲基-5-溴吡啶；5-溴-3-甲基-2-吡啶甲腈
• 英文名称: 5-bromo-3-methylpicolinonitrile
• 英文别名: 5-bromo-3-methylpyridine-2-carbonitrile；5-bromo-3-methyl-2-cyanopyridine
• CAS: 156072-86-5
• 化学式: C₇H₅BrN₂
• 分子量: 197.034
• InChiKey: YPCLLVYLWXIIBW-UHFFFAOYSA-N

物化性质

• 沸点：
  283.6±35.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-bromo-3-methylpyridine-2-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-bromo-3-methylpyridine-2-carbonitrile
CAS number: 156072-86-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BrN2
Molecular weight: 197.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-3-甲基吡啶-2-甲腈 在 三氟甲磺酸 、 硫酸 、 三乙胺 、 N,N-二甲基甲酰胺 、 lithium diisopropyl amide 、 三氯氧磷 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 30.0h， 生成 4-(3,10-dibromo-8-methyl-5,6-dihydro-11H-benzo-[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine ethylcarbamate
  参考文献：
  名称：

  Analogues of 1-(3,10-Dibromo-8-chloro-6,11-dihydro-5 H -benzo[5,6]-cyclohepta[1,2- b ]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase

  摘要：

  The synthesis of several 4-pyridylacetyl N-oxide derivatives of 4-(3-bromo-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]-pyridin-11-yl)pi perazine/piperidine 3 is described. This study was aimed at identifying fomesyl protein transferase (FPT) inhibitors in these two series of tricycles containing different phenyl ring substituents. The in vitro activity profile of the initial group of compounds 7a-7g led to the synthesis of the 8-methyl-10-methoxy and 8-methyl-10-bromo analogues 7i, 13i, and 13j. The 11R(-) enantiomers of these compounds were found to exhibit potent in vitro FPT inhibition activity.

  DOI：

  10.1016/s0968-0896(99)00103-0
• 作为产物：
  描述：

  2-氨基-3-甲基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 ammonium acetate 、 氢溴酸 、 溴 、 sodium nitrite 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 8.5h， 生成 5-溴-3-甲基吡啶-2-甲腈
  参考文献：
  名称：

  吡啶酮-氨基衍生物作为MNK1 / 2抑制剂的设计，合成和生物学评估。

  摘要：

  真核翻译起始因子4E（eIF4E）的过度磷酸化在mRNA翻译失调和肿瘤细胞信号激活中起主要作用。eIF4E仅被Ser209上的促分裂原活化蛋白激酶相互作用的激酶1和2（MNK1 / 2）磷酸化。因此，MNK1 / 2抑制剂可以降低p-eIF4E的水平并调节肿瘤相关的信号通路。合成了一系列吡啶酮-氨基衍生物，并作为MNK1 / 2抑制剂进行了评估。几种化合物对MNK1 / 2表现出极大的抑制活性，某些化合物对血液癌细胞系表现出中度至优异的抗增殖能力。特别地，化合物42i（MNK1 IC50 = 7.0 nM； MNK2 IC50 = 6.1 nM）被证明是针对TMD-8细胞系最有效的化合物，IC50值为0.91μM。此外，42i可以阻断CT-26细胞系中eIF4E的磷酸化水平，42i可以显着抑制CT-26同种异体移植模型的肿瘤生长。这些结果表明，化合物42i是有效治疗结肠癌的有希望的MNK1

  DOI：

  10.1016/j.bmc.2019.02.007

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015180612A1

  公开（公告）日：2015-12-03

  Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

  揭示了新型视黄醇相关孤儿受体γ（RORγ）调节剂及其在通过RORγ介导的疾病治疗中的应用。
• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof
  申请人：Wu Frank

  公开号：US20140093505A1

  公开（公告）日：2014-04-03

  The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

  本发明涉及一种由通式（I）表示的吡啶萘啉化合物，其具有双重PI3K和mTOR抑制作用，以及其药学上可接受的盐、立体异构体和氘代物，其中R1、R2、R3、R4、R5、R6、R7和X如规范中所定义；本发明还涉及一种制备所述化合物的方法，含有所述化合物的药物组合物和药物配方，以及所述化合物在治疗和/或预防增殖性疾病以及制造用于治疗和/或预防增殖性疾病的药物的用途。
• DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
  申请人：Samumed, LLC

  公开号：US20190127370A1

  公开（公告）日：2019-05-02

  Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

  本公开涉及使用二氮萘化合物或其类似物治疗通过激活Wnt途径信号传导特征的疾病的方法。更具体地，本公开涉及在治疗由Wnt途径信号传导激活所特征化的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病、炎症、自身免疫疾病和骨关节炎）中使用二氮萘化合物或其类似物，以及调节由Wnt途径信号传导介导的细胞事件，以及与DYRK1A过表达相关的神经病症/紊乱/疾病。
• Phthalazine, aza- and diaza-phthalazine compounds and methods of use
  申请人：Tasker Andrew

  公开号：US20060199817A1

  公开（公告）日：2006-09-07

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , B, R 1 , R 2 , R 3 and R 4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

  本发明包括一类新的化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症及相关状况。这些化合物的通用公式为I 其中A 1 ，A 2 ，B，R 1 ，R 2 ，R 3 和R 4 在此定义。该发明还包括包括一个或多个I公式化合物的药物组合物，以及使用这些化合物和组合物治疗激酶介导的疾病，包括类风湿性关节炎，银屑病和其他炎症性疾病，以及用于制备I公式化合物的中间体和工艺。